|
287 Companies |
|
339 Products |
|
339 Products |
|
208 Mechanisms of Action |
|
11 Trials |
|
3331 News |
|
| «12...57585960616263646566676869 |
- Enrollment change: Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer (clinicaltrials.gov) - Sep 20, 2011
P2, N=2, Completed, Sponsor: AHS Cancer Control Alberta
N=53 --> 2
- Trial completion: Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer (clinicaltrials.gov) - Sep 20, 2011
P2, N=2, Completed, Sponsor: AHS Cancer Control Alberta
N=53 --> 2 Not yet recruiting --> Completed
- Sutent (sunitinib) / Pfizer
Trial completion, Surgery, Metastases: Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer (clinicaltrials.gov) - Sep 20, 2011
P=N/A, N=20, Completed, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment change: Non Interventional Post Marketing Programme in Neuroendocrine Tumours (clinicaltrials.gov) - Sep 19, 2011
P=N/A, N=40, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed N=50 --> 40
- | Cyramza (ramucirumab) / Eli Lilly
Trial completion, Monotherapy: Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy (clinicaltrials.gov) - Sep 19, 2011
P2, N=42, Completed, Sponsor: Eli Lilly and Company
N=50 --> 40 Active, not recruiting --> Completed
- Trial termination: Liver Transplantation for Cholangiocarcinoma (clinicaltrials.gov) - Sep 18, 2011
P=N/A, N=5, Terminated, Sponsor: University of Utah
Active, not recruiting --> Completed Active, not recruiting --> Terminated; study procedures have become standard of care as patients seeking Model for End-Stage Liver Disease (MELD) exception points for cholangiocarcinoma
- Enrollment change: Liver Transplantation for Cholangiocarcinoma (clinicaltrials.gov) - Sep 18, 2011
P=N/A, N=5, Terminated, Sponsor: University of Utah
Active, not recruiting --> Terminated; study procedures have become standard of care as patients seeking Model for End-Stage Liver Disease (MELD) exception points for cholangiocarcinoma N=50 --> 5
- ||| Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment closed: Ovarian Cancer Vaccine for Patients in Remission (clinicaltrials.gov) - Sep 18, 2011
P2b, N=63, Active, not recruiting, Sponsor: Prima BioMed Ltd
N=50 --> 5 Recruiting --> Active, not recruiting
- New P3 trial: Antioxidant Supplement and Reduction of Metachronous Adenomas of the Large Bowel: a Double Blind Randomized Trial (clinicaltrials.gov) - Sep 13, 2011
P3, N=411, Terminated, Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
- metformin / Generic mfg.
New P2 trial, IO biomarker, Surgery: Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery (clinicaltrials.gov) - Sep 12, 2011
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Apocept (asunercept) / Apogenix
Enrollment closed: APG101 in Glioblastoma (clinicaltrials.gov) - Sep 11, 2011
P2, N=83, Active, not recruiting, Sponsor: Apogenix GmbH
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- lorvotuzumab mertansine (IMGN901) / ImmunoGen
Enrollment closed: BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Sep 11, 2011
P1, N=44, Active, not recruiting, Sponsor: ImmunoGen, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | HuMax-EGFR (zalutumumab) / Genmab
Trial completion: Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) (clinicaltrials.gov) - Sep 8, 2011
P1/2, N=31, Completed, Sponsor: Genmab
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Provenge (sipuleucel-T) / Bausch Health
New P2 trial, Metastases: Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer (clinicaltrials.gov) - Sep 7, 2011
P2, N=60, Active, not recruiting, Sponsor: Dendreon
- |||| Enrollment open: Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy (clinicaltrials.gov) - Sep 7, 2011
P4, N=454, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Trial completion: Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma (clinicaltrials.gov) - Sep 6, 2011
P=N/A, N=151, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Biomarker, Enrollment closed: Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor (clinicaltrials.gov) - Sep 1, 2011
P=N/A, N=20, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors (clinicaltrials.gov) - Sep 1, 2011
P2, N=56, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || carboplatin / Generic mfg.
New P2/3 trial: GeparSixto: Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (clinicaltrials.gov) - Aug 30, 2011
P2/3, N=595, Completed, Sponsor: German Breast Group
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
Enrollment open, Metastases: IXOGoo1: First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. (clinicaltrials.gov) - Aug 29, 2011
P2, N=50, Recruiting, Sponsor: AHS Cancer Control Alberta
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| erlotinib / Generic mfg.
Trial completion, Metastases: Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung (clinicaltrials.gov) - Aug 29, 2011
P2, N=54, Completed, Sponsor: New Mexico Cancer Care Alliance
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
New P2 trial, Combination therapy: Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 28, 2011
P2, N=91, Completed, Sponsor: Wei Guo
- ||||| Lipotecan (TLC388) / Taiwan Liposome Company
New P1/2 trial, Metastases: A Dose-escalation Study of Lipotecan (clinicaltrials.gov) - Aug 28, 2011
P1/2, N=60, Recruiting, Sponsor: Taiwan Liposome Company
- albumin-bound paclitaxel / Generic mfg.
Trial completion: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 22, 2011
P2, N=51, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial: Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG) (clinicaltrials.gov) - Aug 16, 2011
P1, N=10, Recruiting, Sponsor: University of Iowa
- New P3 trial: Net-Pac;NetPac: Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer (clinicaltrials.gov) - Aug 15, 2011
P3, N=5, Terminated, Sponsor: CHIR-Net
- Vectibix (panitumumab) / Amgen
New P2 trial: SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment (clinicaltrials.gov) - Aug 15, 2011
P2, N=11, Terminated, Sponsor: Gesellschaft fur Medizinische Innovation
- cisplatin / Generic mfg., paclitaxel / Generic mfg., gefitinib / Generic mfg.
Trial termination, Surgery, Metastases: Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery (clinicaltrials.gov) - Aug 14, 2011
P2, N=36, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Closed due to early stopping rule-Low accrual
- | futuximab/modotuximab (S95026) / Servier
New P2 trial, Metastases: Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy (clinicaltrials.gov) - Aug 14, 2011
P2, N=26, Completed, Sponsor: Symphogen A/S
- dovitinib (TKI258) / Novartis, Oncoheroes
New P2 trial, Monotherapy: Dovitinib in Adenoid Cystic Carcinoma (clinicaltrials.gov) - Aug 14, 2011
P2, N=33, Recruiting, Sponsor: Seoul National University Hospital
- | MB07133 / Xi'an XinTong Pharma
Enrollment change: Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 10, 2011
P1/2, N=28, Completed, Sponsor: Ligand Pharmaceuticals
Active, not recruiting --> Terminated; Closed due to early stopping rule-Low accrual N=36 --> 28
- Foscan (temoporfin) / ABVC BioPharma
New P2 trial, Metastases: Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers (clinicaltrials.gov) - Aug 10, 2011
P2, N=1, Terminated, Sponsor: University of Arkansas
- Trial completion: T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant (clinicaltrials.gov) - Aug 10, 2011
P2b, N=100, Completed, Sponsor: National Cancer Institute (NCI)
N=36 --> 28 Active, not recruiting --> Completed
- | Votrient (pazopanib) / Novartis, BeiGene
New P1 trial, Combination therapy, Surgery, Metastases: Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery (clinicaltrials.gov) - Aug 8, 2011
P1, N=24, Active, not recruiting, Sponsor: University of Washington
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Monotherapy, Surgery: CHIRON: Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery (clinicaltrials.gov) - Aug 8, 2011
P1/2, N=34, Completed, Sponsor: Cliniques universitaires Saint-Luc- Universit
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction (clinicaltrials.gov) - Aug 8, 2011
P4, N=400, Completed, Sponsor: University Hospital, Linkoeping
Recruiting --> Completed Active, not recruiting --> Completed
- temozolomide / Generic mfg.
Enrollment change: Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma (clinicaltrials.gov) - Aug 7, 2011
P2, N=1, Completed, Sponsor: Herbert Newton
Active, not recruiting --> Completed N=60 --> 1
- sorafenib / Generic mfg.
Trial completion, Surgery: Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer (clinicaltrials.gov) - Aug 7, 2011
P2, N=5, Completed, Sponsor: University of Washington
N=60 --> 1 Active, not recruiting --> Completed
- temozolomide / Generic mfg.
Trial completion: Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma (clinicaltrials.gov) - Aug 7, 2011
P2, N=1, Completed, Sponsor: Herbert Newton
Active, not recruiting --> Completed No longer recruiting --> Completed